US$ 23.30
companies working on glp-1 drugs Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 Large employers embrace GLP-1s
Description
Eli Lillys retatrutide (TRIUMPH-4 trial) achieved up to 28.7% mean weight loss at 12 mg (vs 22.5% with tirzepatide/Zepbound), plus 75.8% knee OA pain reduction
Endoplasmic reticulum stress, obesity and diabetes

Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study

He et al., 2022)

2018;236(1):R29-R42
